Sending Office: Honorable David Scott
Support Endometrial Cancer Research & Awareness
I urge you to join me in re-introducing the Endometrial Cancer Research and Education Act. Endometrial cancer is the most common form of uterine cancer, and the 4th most common cancer among women, after breast, lung, and colon cancers. It is a
cancer of the lining of the uterus (endometrium), which mainly affects postmenopausal women, with the most women diagnosed between ages 55 and 64.
According to the American Cancer Society, about 65,620 new cases of endometrial cancer will be diagnosed, and an estimated 12,590 women could die from endometrial cancer this year. Unlike most other types of cancer, endometrial cancer incidences have been
increasing in the United States among all women, particularly the aggressive cancer sub-types. Recent indicators show that incidence rates for endometrial cancers are rising, particularly among African American and Asian women. African American women have
significantly higher incidence rates of aggressive endometrial cancers compared with women of other racial and ethnic backgrounds, and these women are 2.5 times more likely to die of endometrial cancer. .
The Endometrial Cancer Research and Education Act of 2020 would coordinate and increase research into the racial disparities in endometrial cancer deaths and educate patients and medical professionals about these disparities. This legislation would direct
the NIH Director to expand, intensify, and coordinate programs to conduct and support research with respect to endometrial cancer.
The Endometrial Cancer Research and Education Act would also authorize $500,000 annually from fiscal years 2021 through 2023 to support the National Institute of Health’s (NIH) and the Centers for Disease Control and Prevention’s (CDC) work to create an
Endometrial Cancer Public Education Program, which would inform healthcare providers about changes in the incidence, risk and elevated risk of endometrial cancer for minority women, and outline the range of available treatments for endometrial cancer.
I ask you to join me in highlighting this important women’s health issue and ensuring that patients and providers learn more about risk factors for endometrial cancer. The deadline to join as an original cosponsor is COB February 5, 2020. If you would
like to sign on as a cosponsor or if you have additional questions, please contact Ijeoma Egekeze in my office at firstname.lastname@example.org.
Member of Congress
e-Dear Colleague version 2.0